Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
Open Access
- 21 November 2017
- journal article
- review article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 5 (1), 95
- https://doi.org/10.1186/s40425-017-0300-z
Abstract
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the same immunologic mechanisms responsible for the drugs’ therapeutic effects, namely blockade of inhibitory mechanisms that suppress the immune system and protect body tissues from an unconstrained acute or chronic immune response. Skin, gut, endocrine, lung and musculoskeletal irAEs are relatively common, whereas cardiovascular, hematologic, renal, neurologic and ophthalmologic irAEs occur much less frequently. The majority of irAEs are mild to moderate in severity; however, serious and occasionally life-threatening irAEs are reported in the literature, and treatment-related deaths occur in up to 2% of patients, varying by ICI. Immunotherapy-related irAEs typically have a delayed onset and prolonged duration compared to adverse events from chemotherapy, and effective management depends on early recognition and prompt intervention with immune suppression and/or immunomodulatory strategies. There is an urgent need for multidisciplinary guidance reflecting broad-based perspectives on how to recognize, report and manage organ-specific toxicities until evidence-based data are available to inform clinical decision-making. The Society for Immunotherapy of Cancer (SITC) established a multidisciplinary Toxicity Management Working Group, which met for a full-day workshop to develop recommendations to standardize management of irAEs. Here we present their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy.Keywords
This publication has 93 references indexed in Scilit:
- Ipilimumab-Associated Colitis: CT FindingsAmerican Journal of Roentgenology, 2013
- The Influence of Anti-TNF Therapy on the Course of Chronic Hepatitis C Virus Infection in Patients with Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Diagnostic Performance of CMR Imaging Compared With EMB in Patients With Suspected MyocarditisJACC: Cardiovascular Imaging, 2012
- Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete RemissionJournal of Clinical Oncology, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV MelanomaClinical Cancer Research, 2009
- Anti-CTLA4 Antibody–Induced Lupus NephritisThe New England Journal of Medicine, 2009
- α-CTLA-4 mAb-associated PanenteritisThe American Journal of Surgical Pathology, 2008
- Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac ProblemsClinical Cancer Research, 2008